论文部分内容阅读
目的:对比CLU、PKCα基因在化疗前及化疗后卵巢癌组织表达的差异。方法:卵巢癌患者60例,包括紫杉醇化疗组(Ⅰ组)和未化疗组(Ⅱ组)各30例,提取卵巢癌组织总RNA,反转录为cDNA。用荧光实时定量PCR方法检测60份标本中CLU、PKCα,MDR基因的表达。结果:CLU、PKCα基因在Ⅰ组、Ⅱ组均有较高的表达阳性率,分别为96.67%与100%、100%与100%,两组间无显著差异(P>0.05)。PKCα基因在化疗组表达Ct值3.530±0.99584,显著高于未化疗组3.003±0.65074(P<0.05)。但术前化疗组及化疗复发组之间无显著差异(P>0.05)。MDR表达阳性组织中,CLU基因的表达Ct值4.3487±1.41353,显著高于MDR表达阴性组织的3.2955±1.52114(P<0.05)。结论:PKCα在化疗后卵巢癌组织中高表达,可能在卵巢癌紫杉醇化疗耐药中起重要作用。CLU可能与MDR介导的卵巢癌多药耐药有关。CLU、PKCα表达显著相关,提示两个基因共同参与了卵巢癌耐药机制。
OBJECTIVE: To compare the differences of CLU and PKCα gene expression between ovarian cancer tissues before and after chemotherapy. Methods: 60 patients with ovarian cancer, including paclitaxel chemotherapy group (Ⅰ group) and non-chemotherapy group (Ⅱ group), 30 cases of total RNA extracted from ovarian cancer, reverse transcribed to cDNA. Real-time quantitative PCR was used to detect the expression of CLU, PKCα and MDR in 60 samples. Results: The positive expression rates of CLU and PKCα in group Ⅰ and group Ⅱ were 96.67% and 100%, 100% and 100%, respectively. There was no significant difference between the two groups (P> 0.05). The expression of PKCα in the chemotherapy group was 3.530 ± 0.99584, which was significantly higher than that in the non-chemotherapy group (3.003 ± 0.65074, P <0.05). However, there was no significant difference between preoperative chemotherapy group and chemotherapy recurrence group (P> 0.05). In MDR positive tissues, the Ct value of CLU gene was 4.3487 ± 1.41353, which was significantly higher than that of MDR negative tissues (3.2955 ± 1.52114, P <0.05). Conclusion: PKCα is overexpressed in ovarian cancer after chemotherapy, which may play an important role in chemoresistance of paclitaxel in ovarian cancer. CLU may be related to MDR-mediated multidrug resistance of ovarian cancer. CLU, PKCα expression was significantly correlated, suggesting that the two genes involved in the mechanism of drug resistance in ovarian cancer.